{"id":51953,"date":"2022-12-14T11:02:13","date_gmt":"2022-12-14T10:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/insights-on-the-knee-surgeries-and-arthroplasty-pain-management-therapeutics-global-market-to-2030-by-drug-distribution-channel-and-region-researchandmarkets-com\/"},"modified":"2022-12-14T11:02:13","modified_gmt":"2022-12-14T10:02:13","slug":"insights-on-the-knee-surgeries-and-arthroplasty-pain-management-therapeutics-global-market-to-2030-by-drug-distribution-channel-and-region-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/insights-on-the-knee-surgeries-and-arthroplasty-pain-management-therapeutics-global-market-to-2030-by-drug-distribution-channel-and-region-researchandmarkets-com\/","title":{"rendered":"Insights on the Knee Surgeries and Arthroplasty Pain Management Therapeutics Global Market to 2030 – by Drug, Distribution Channel and Region – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market – Size, Share, Outlook, and Opportunity Analysis, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nMany types of medicines are available to help control pain, including opioids, non-steroidal anti-inflammatory drugs (NSAIDs), Acetaminophen, etc. Medications help people feel more comfortable, allowing one to start moving sooner, get the strength back more quickly, and recover from knee surgeries and arthroplasty faster.\n<\/p>\n

\nFurthermore, increasing number of total knee arthroplasty is expected to drive the market growth over the forecast period\n<\/p>\n

\nFor instance, according to data published by National Center for Biotechnology Information in 2017, the number of total knee arthroplasty is estimated to range between 60,000 and 70,000 per year in Brazil.\n<\/p>\n

\nMarket Dynamics<\/strong>\n<\/p>\n

\nIncreasing research and development activities by the key players for the development and launch of knee surgeries and arthroplasty pain management drugs are expected to drive the growth of the global knee surgeries and arthroplasty pain management therapeutics market over the forecast period.\n<\/p>\n

\nFor instance, in May 2021, Allay Therapeutics, a clinical-stage biotechnology company, pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration. The existing post-surgical pain products have shown effectiveness for a maximum of three days after a single dose. The data come from a Phase 1b\/2a clinical study of Allay’s first candidate, ATX-101, in development to treat pain after total knee arthroplasty (replacement) or TKA surgery.\n<\/p>\n

\nMoreover, increasing approval of drug is also expected to boost the market growth. For instance, in march 2020, GlaxoSmithKline Plc. announced that the U.S. Food and Drug Administration had approved Advil Dual Action with Acetaminophen, as an (OTC) over-the-counter product for pain relief. Advil Dual Action gives relief for various symptoms and is the major formulation that merges acetaminophen and ibuprofen, 2 strong ingredients indicated for over-the-counter pain relief that work in different ways.\n<\/p>\n

\nKey features of the study:<\/strong>\n<\/p>\n